IO Biotech, Inc. IOBT 深 滬
已收盤 12-12 16:00:00 美东时间
0.8076
-0.042
-5.00%
華盛通- 最 高0.8622
- 今 開0.86
- 成交量 33.55万股
- 最 低 0.80
- 昨 收 0.8501
- 總市值 5320.54万
- 52周最高 2.79
- 市盈率 靜 --
- 換手率 0.51%
- 52周最低 0.3234
- 委 比 83.40%
- 總股本 6588.09万
- 歷史最高 17.88
- 量 比 0.41
- 振 幅 7.32%
- 歷史最低 0.3234
- 每 手 1
- 風險率 0.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多IO Biotech Announces Participation in Upcoming December Investor Conferences
IO Biotech will participate in the 8th Annual Evercore Healthcare Conference in Florida on December 2, 2025, and the Piper Sandler Annual Healthcare Conference in New York on December 2025. Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO, will host fireside chats and investor meetings. Both events will be webcast and available on IO Biotech's website. IO Biotech develops immune-modulatory cancer vaccines using its T-win® platform, ad...
11-26 15:46
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Olema Pharmaceuticals (NASDAQ:OLMA) stock increased by 137.7% to $20.2...
11-19 01:06
IO Biotech Presents at Jefferies Global Healthcare Conference
IO Biotech ( ($IOBT) ) has provided an announcement. IO Biotech, Inc. announced...
11-18 19:58
IO Biotech Q3 EPS $(0.13) Beats $(0.34) Estimate
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.34) by 61.19 percent. This is a 63.89 percent increase over losses of $(0.36) per share from the
11-14 21:11
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
IO Biotech reported interim results for Phase 3 trial IOB-013 for advanced melanoma, showing clinically relevant progression-free survival (PFS) improvements across subgroups though narrowly missing statistical significance. The company plans to meet with the FDA in December to discuss a potential new Phase 3 registrational trial. IO Biotech also presented pre-clinical data for IO112 and IO170 candidates at the SITC Annual Meeting. The company en...
11-14 13:05
IO Biotech To Present New Pre-Clinical Data For Next Vaccine Candidate, IO112, And Additional Candidate, IO170, At SITC 2025
Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted
11-07 22:06
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 27, 2025 /PRNewswire/ -- The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce t...
10-27 20:30
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
10-23 10:06
IO Biotech Phase 3: Cylembio Plus KEYTRUDA Extends Median PFS To 19.4 Months In First-Line Advanced Melanoma, Showing Clinically Meaningful Improvement Despite Narrow Miss On Statistical Significance
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS)
10-20 14:48
